Prosecution Insights
Last updated: April 19, 2026
Application No. 18/030,629

DEFIBRILLATOR INTERFACE DEVICE FOR ATRIAL CARDIOVERSION THERAPY

Final Rejection §102§103
Filed
Apr 06, 2023
Examiner
LEVICKY, WILLIAM J
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Native Cardio Inc.
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
3y 5m
To Grant
98%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
397 granted / 572 resolved
-0.6% vs TC avg
Strong +29% interview lift
Without
With
+29.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
56 currently pending
Career history
628
Total Applications
across all art units

Statute-Specific Performance

§101
7.8%
-32.2% vs TC avg
§103
38.1%
-1.9% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
24.3%
-15.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 572 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 2/18/2026 have been fully considered but they are not persuasive. Applicant argues that the claims require “an output terminal configured to deliver an output signal comprising at least one discrete pulse to a plurality of heart lead wires when coupled thereto.” Applicant argues that Sullivan’s device is configured to deliver energy through external electrodes and paddles applied to a patient’s chest. The Applicant argues Sullivan does not disclose or teach an output terminal configured to couple to “heart lead wires” as recited in claims 1, 6 and 16. The examiner respectfully disagrees as the output terminal is claimed as configured to deliver an output signal to a plurality of heart lead wires. Sullivan teaches an output of Element 50 which is coupled to (heart lead) wires 54 to carry the pulse to the patient (e.g. Figure 1 and Column 5, lines 1-19). Claim Rejections - 35 USC § 102 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 1-8, 10 and 16-22 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sullivan et al (US Patent 6,539,258). Referring to Claim 1, Sullivan et al teaches a defibrillator interface device comprising: an input terminal configured to receive an input signal from a defibrillator when coupled thereto (e.g. Figure 1, input from 52); an output terminal configured to deliver an output signal comprising at least one discrete pulse to a plurality of heart lead wires when coupled thereto (e.g. Figure 1, output at 54 to the patient; the examiner notes the heart lead wires are not positively recited but are functionally recited); an attenuation circuit configured to convert the input signal into the output signal such that a pulse energy for each discrete pulse in the output signal is less than 6 Joules (e.g. Figure 1, Element 50 and Column 6 lines 20-30). Referring to Claim 2, Sullivan et al teaches the defibrillator interface device of claim 1, wherein the pulse energy is less than 0.2 Joules (e.g. Claim 7 discloses the output is approximately 0.2 joules or less). Referring to Claim 3, Sullivan et al teaches the defibrillator interface device of claim 1, wherein at least one of the discrete pulses of the output signal comprises a square waveform, a plateau waveform, a truncated exponential waveform, a rounded waveform, or a monophasic or biphasic form thereof (e.g. Column 10 lines 17-35). Referring to Claim 4, Sullivan et al teaches the defibrillator interface device of claim 1, further comprising a cardioversion cable coupled between the output terminal and the plurality of heart lead wires (e.g. Figures 1 and 2, output 54 and Column 5 lines 15-20). Referring to Claim 5, Sullivan et al teaches the defibrillator interface device of claim 1, wherein the input terminal is configured to couple to the defibrillator via a cable connector without physical contact with defibrillator paddles (e.g. Figures 1 and 2 and Column 7 lines 16-20). Referring to Claim 6, Sullivan et al teaches a defibrillator interface device comprising: an input terminal configured to couple to a defibrillator (e.g. Figure 1, input from 52); an output terminal configured to couple to a plurality of heart lead wires (e.g. Figure 1, output at 54 to the patient; the examiner notes the heart lead wires are not positively recited but are functionally recited); an attenuation circuit configured to couple the input terminal to the output terminal, wherein the attenuation circuit comprises a plurality of resistors arranged in a voltage divider configuration, wherein each of the plurality of resistors exhibits a resistance of less than 1 kΩ (e.g. Figure 1, Element 50 and Figures 2 illustrates the divider circuit and Column 7 lines 30-35 discloses resistors in the range of 5-100 ohms). Referring to Claim 7, Sullivan et al teaches the defibrillator interface device of claim 6, wherein the input terminal is coupled directly to the attenuation circuit without any intervening voltage discharge tubes (e.g. Figure 2 illustrates the voltage divider circuit and does not require voltage discharge tubes). Referring to Claim 8, Sullivan et al teaches the defibrillator interface device of claim 6, wherein the resistors are selected such that a pulse energy of output pulses generated by the attenuation circuit is less than 6 Joules (e.g. Column 6 lines 20-30). Referring to Claim 10, Sullivan et al teaches the defibrillator interface device of claim 6, wherein the input terminal is configured to couple to the defibrillator via a cable connector without physical contact with defibrillator paddles (e.g. Figures 1 and 2 and Column 7 lines 16-20). Referring to Claim 16, Sullivan et al teaches a method of performing atrial cardioversion, the method comprising: receiving, by an input terminal of a defibrillator interface device, an input pulse from a defibrillator via a cable connector coupling the defibrillator to the input terminal (e.g. Figure 1 input 52 from defibrillator device 8); converting, by an attenuation circuit, the input pulse into an output pulse having a pulse energy of less than 6 Joules (e.g. Figure 1, Element 50 and Column 6 lines 20-30); transmitting the output pulse to a patient's heart via a plurality of heart lead wires in contact therewith (e.g. Figures 1 and 2, output 54 and Column 5 lines 15-20). Referring to Claim 17, Sullivan et al teaches the method of claim 16, wherein the pulse energy is less than 0.2 Joules (e.g. Claim 7 discloses the output is approximately 0.2 joules or less). Referring to Claim 18, Sullivan et al teaches the method of claim 16, wherein the output pulse comprises a square waveform, a plateau waveform, a truncated exponential waveform, a rounded waveform, or a monophasic or biphasic form thereof (e.g. Column 10 lines 17-35). Referring to Claim 19, Sullivan et al teaches the method of any of claim 16, further comprising: coupling the input terminal of the defibrillator interface device via the cable connector without physically contacting the input terminal with defibrillator paddles (e.g. Figures 1 and 2 and Column 7 lines 16-20). Referring to Claim 20, Sullivan et al teaches the method of claim 16, wherein the attenuation circuit is electrically coupled to the input terminal without any intervening voltage discharge tubes (e.g. Figure 2 illustrates the voltage divider circuit and does not require voltage discharge tubes). Referring to Claim 21, Sullivan et al teaches the method of claim 16, wherein successful atrial cardioversion is achieved at defibrillation threshold of greater than 0.1 J and less than 1 J (e.g. Column 6 lines 20-30). Referring to Claim 22, Sullivan et al teaches the method of claim 21, wherein the successful atrial cardioversion is achieved using single-stage energy delivery (e.g. Column 9 lines 56-Column 10 line 56 disclose the energy delivery resulting from a single biphasic shock). Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Sullivan et al (US Patent 6,539,258) in view of Wahler et al (US Publication 2013/0131526). Referring to Claim 9, Sullivan et al teaches the defibrillator interface device of claim 6, except further comprising at least one voltage discharge tube coupled in parallel between the attenuation circuit and the output terminal. Wahler et al teaches that it is known to use gas discharge tube in parallel between the circuit(s) and output terminal as set forth in Figure 1, Element 125 to provide protection of the circuit(s) from overvoltages. It would have been obvious before the effective filing date of the claimed invention to one having ordinary skill in the art to modify the system as taught by Sullivan et al, with gas discharge tube in parallel between the circuits and output terminal as taught by Wahler et al, since such a modification would provide the predictable results of protection of the circuit(s) from overvoltages. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to William J Levicky whose telephone number is (571)270-3983. The examiner can normally be reached Monday-Thursday 8AM-5PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Hamaoui can be reached at (571)270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /William J Levicky/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Apr 06, 2023
Application Filed
Aug 14, 2025
Non-Final Rejection — §102, §103
Feb 18, 2026
Response Filed
Mar 20, 2026
Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589241
Dual Sensor Electrodes for Providing Enhanced Resuscitation Feedback
2y 5m to grant Granted Mar 31, 2026
Patent 12569690
CARDIAC CONTRACTILITY MODULATION FOR ATRIAL ARRHYTHMIA PATIENTS
2y 5m to grant Granted Mar 10, 2026
Patent 12569686
CHRONICALLY IMPLANTABLE SYSTEMS AND METHODS FOR AFFECTING CARDIAC CONTRACTILITY AND/OR RELAXATION
2y 5m to grant Granted Mar 10, 2026
Patent 12558557
DISCRIMINATION OF SUPRAVENTRICULAR TACHYCARDIAS IN COMBINED CCM-ICD DEVICE
2y 5m to grant Granted Feb 24, 2026
Patent 12544580
DETACHABLE LEADLESS PACEMAKER SYSTEM FOR CARDIAC CONDUCTION BUNDLE PACING
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
98%
With Interview (+29.1%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 572 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month